The aim of this study was to demonstrate whether there is a correlation between transepidermal water loss (TEWL) and the severity of skin lesions in cats with feline atopic dermatitis (AD). The severity of symptoms was determined by using 2 scoring systems for clinically assessing the skin lesions in cats: Scoring Feline Allergic Dermatitis (SCORFAD) and Feline Extent and Severity Index (FeDESI). Such a correlation between TEWL and systems for clinically evaluating symptoms has already been shown in humans and dogs. Measurements were taken in 18 European Shorthair cats: 11 females and 7 males. Scores were calculated using SCORFAD and FeDESI and TEWL was measured in 7 areas of the body. Correlations were calculated between SCORFAD and TEWL and between FeDESI and TEWL for each body region and the average TEWL was also calculated with each system. Positive correlations were found between SCORFAD and TEWL in 3 of the examined areas: thorax ( = 0.44, = 0.02); axilla ( = 0.39, = 0.04); and forelimb ( = 0.55, = 0.02). A correlation was also found between the average TEWL and SCORFAD ( = 0.41, = 0.03). In the case of FeDESI, a correlation was found in the forelimb ( = 0.53, = 0.02), but no correlation was found between FeDESI and the average TEWL. The results obtained showed that TEWL can be used as an additional tool in clinically assessing atopic dermatitis in cats, although it seems to be less useful in cats than in humans.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168015 | PMC |
Br J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFDermatologie (Heidelb)
January 2025
Psychoneuroimmunologie Labor, Klinik für Psychosomatik und Psychotherapie, Justus-Liebig-Universität Gießen, Aulweg 123, 35385, Gießen, Deutschland.
Background: Atopic dermatitis is perhaps the most comprehensively studied skin disease in psychosomatic medicine and psychoneuroimmunology. Its biopsychosocial conceptualization incorporates psychodynamic as well as behavioral and systemic considerations. At the same time, there is also extensive biological knowledge of the neuroendocrine-immune control of barrier and immune function, characterized through animal experiments and translational clinical studies.
View Article and Find Full Text PDFACS Nano
January 2025
College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS).
View Article and Find Full Text PDFClin Exp Allergy
January 2025
Department of Pediatrics, Okayama University, Graduate School of Medicine, Density and Pharmaceutical Science, Okayama, Japan.
Am J Vet Res
January 2025
Waltham Petcare Science Institute, Waltham on the Wolds, Leicestershire, United Kingdom.
Objective: To evaluate the use of collar-mounted accelerometers to objectively monitor treatment outcomes in canine pruritus.
Methods: Observational data from 1,803 dogs from 2019 through 2023 were retrospectively analyzed to evaluate the efficacy of collar-mounted accelerometers to assess treatment efficacy for pruritic canine skin diseases. Accelerometer measurements were joined to electronic health records to establish symptoms, diagnoses, and interventions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!